. Invs and . Prévalence, [cité 9 déc 2015]. http://www.invs.sante.fr/Dossiers-thematiques/Maladies-chroniques-et- traumatismes

. Invs, . Prévalence-et-incidence-du-diabète, and . Et-mortalité-liée-au-diabète-en-france, Synthése épidémiologique. [cité 16 déc 2015

. Invs, http://www.invs.sante.fr/fr/Dossiers-thematiques/Maladies-chroniques-et- traumatismes, 2007.

. Assurance-maladie, Améliorer la qualité du système de santé et maîtriser les dépenses. [cité 13 déc 2015

K. Khunti, M. Wolden, B. Thorsted, M. Andersen, and M. Davies, Clinical Inertia in People With Type 2 Diabetes: A retrospective cohort study of more than 80,000 people, Diabetes Care, vol.36, issue.11, pp.3411-3418, 2013.
DOI : 10.2337/dc13-0331

S. Paul, K. Klein, B. Thorsted, M. Wolden, and K. Khunti, Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes, Cardiovascular Diabetology, vol.311, issue.22, p.100, 2015.
DOI : 10.1186/s12933-015-0260-x

W. Bennett, N. Maruthur, S. Singh, J. Segal, and L. Wilson, Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations, Annals of Internal Medicine, vol.154, issue.9, pp.602-615
DOI : 10.7326/0003-4819-154-9-201105030-00336

E. Moro, N. Allert, R. Eleopra, J. Houeto, T. Phan et al., A decision tool to support appropriate referral for deep brain stimulation in Parkinson???s disease, Journal of Neurology, vol.125, issue.1, pp.83-91, 2009.
DOI : 10.1007/s00415-009-0069-1

M. Persson, T. Mjörndal, B. Carlberg, J. Bohlin, and L. Lindholm, Evaluation of a computer-based decision support system for treatment of hypertension with drugs: retrospective, nonintervention testing of cost and guideline adherence, Journal of Internal Medicine, vol.7, issue.1, pp.87-93, 2000.
DOI : 10.1046/j.1365-2796.2000.00581.x

D. Rodbard and R. Vigersky, Design of a Decision Support System to Help Clinicians Manage Glycemia in Patients with Type 2 Diabetes Mellitus, Journal of Diabetes Science and Technology, vol.4, issue.2, p.402, 2011.
DOI : 10.1056/NEJMoa0808431

A. Garg, N. Adhikari, and H. Mcdonald, Effects of Computerized Clinical Decision Support Systems on Practitioner Performance and Patient Outcomes, JAMA, vol.293, issue.10
DOI : 10.1001/jama.293.10.1223

H. Recosdoc-diabète, Stratégie médicamenteuse du contrôle glycémique du diabète de type 2, 2015.

F. Ampudia-blasco, P. Benhamou, G. Charpentier, A. Consoli, M. Diamant et al., A Decision Support Tool for Appropriate Glucose-Lowering Therapy in Patients with Type 2 Diabetes, Diabetes Technology & Therapeutics, vol.17, issue.3, p.194, 2015.
DOI : 10.1089/dia.2014.0260

D. Berlowitz, A. Ash, M. Glickman, R. Friedman, L. Pogach et al., Developing a Quality Measure for Clinical Inertia in Diabetes Care, Health Services Research, vol.23, issue.7, p.1836, 2005.
DOI : 10.1056/NEJM199309303291401

A. Pfützner, E. Paz-pacheco, E. Allen, R. Frederich, and R. Chen, Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks, Diabetes, Obesity and Metabolism, vol.12, issue.Suppl. 2, pp.567-76, 2011.
DOI : 10.1111/j.1463-1326.2011.01385.x

E. Ferrannini, V. Fonseca, B. Zinman, D. Matthews, B. Ahrén et al., Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy, Diabetes, Obesity and Metabolism, vol.30, issue.2, pp.157-66, 2009.
DOI : 10.1111/j.1463-1326.2008.00994.x

B. Gallwitz, J. Guzman, F. Dotta, B. Guerci, R. Simó et al., Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2

S. Palmer, D. Mavridis, A. Nicolucci, D. Johnson, M. Tonelli et al., Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes, JAMA, vol.316, issue.3, pp.313-337, 201619.
DOI : 10.1001/jama.2016.9400